Zheng, S and Hunter, DJ and Xu, J and Ding, C, Monoclonal antibodies for the treatment of osteoarthritis, Expert Opinion on Biological Therapy, 16, (12) pp. 1529-1540. ISSN 1471-2598 (2016) [Refereed Article]
© 2016 Informa UK Limited, trading as Taylor & Francis Group
Areas covered: In this review, the authors searched the literature on PubMed, EMBASE and the Cochrane Library using keywords, including mAbs, biological agents, OA and osteoarthritis, electronically up to May 2016. They also included abstracts of international conferences. Furthermore, they reviewed experimental and clinical studies of various mAbs targeting different pathological mechanisms of OA, including ADAMTS, Interleukine-1, tumour necrosis factor, never growth factor and vascular endothelial growth factor.
Expert opinion: MAbs for the treatment of OA are under intense investigation and the results for some mAbs (e.g., anti-nerve growth factor mAbs, anti- vascular endothelial growth factor mAbs) are promising. The authors believe that mAb therapy can be a targeted therapeutic approach for the treatment of OA. Future clinical trials are required to evaluate the therapeutic efficacy of these agents by the appropriate selection of specific phenotype for targeted therapy based on the mechanism of drug action.
|Item Type:||Refereed Article|
|Keywords:||Inflammation, OA, DMOADs, mAbs|
|Research Division:||Biomedical and Clinical Sciences|
|Research Group:||Clinical sciences|
|Research Field:||Rheumatology and arthritis|
|Objective Group:||Clinical health|
|Objective Field:||Clinical health not elsewhere classified|
|UTAS Author:||Ding, C (Professor Chang-Hai Ding)|
|Web of Science® Times Cited:||17|
|Deposited By:||Menzies Institute for Medical Research|
Repository Staff Only: item control page